ArticleScientific reports2026
CircPTP4A2 (hsa_circ_0007364) promotes growth and invasion of non-small cell lung cancer by regulating miR-183-5p/EEF2 axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a novel circular RNA (circRNA), circPTP4A2 (hsa_circ_0007364), was reported to promote cervical cancer progression. However, its specific role in non-small cell lung cancer (NSCLC) remains unclear. Here, we observed that circPTP4A2 is significantly upregulated in NSCLC tissues and cell lines. Furthermore, multivariate Cox proportional hazards regression analysis confirmed that high circPTP4A2 expression is independently associated with poor prognosis in NSCLC patients after adjusting for confounding clinicopathological covariates. Knockdown of circPTP4A2 significantly suppressed the proliferation, migration, and invasion capabilities of H1299 and A549 cells. Additionally, we identified miR-183-5p as a direct targeted of circPTP4A2. In NSCLC clinical samples, circPTP4A2 expression showed a negative correlation with miR-183-5p levels. Moreover, we demonstrated that circPTP4A2 enhances the expression of EEF2, a downstream target of miR-183-5p. Collectively, our findings elucidate that circPTP4A2 promotes NSCLC progression by sponging miR-183-5p to upregulate EEF2, suggesting it could be a promising therapeutic target for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.